Pharmafile Logo
Pharmafocus logo
Advanced Search
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …

News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News
astrazeneca_plaque

AZ “disappointment” at heart drug failure

October 5, 2016
Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …

News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016
Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …

News
1280px-epi-pen_1

Mylan’s promised half-price EpiPen not available until year’s end

October 5, 2016
Research and Development, Sales and Marketing Mylan, epipen

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …

News

Roche granted breakthrough therapy designation by FDA

October 5, 2016
Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy

Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …

News
jj_2johnson_and_johnson

Patients’ insulin pumps are revealed to be hackable by J&J

October 4, 2016
Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …

News
roche_side_building

Roche’s Alecensa receives second FDA Breakthrough Therapy Designation

October 4, 2016
Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib

Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …

News
astrazeneca_sign_sky

AstraZeneca’s wins major drug approval by NICE

October 4, 2016
Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …

News
vaccine3a-062568e

Sanofi’s dengue vaccine scores 11th worldwide approval in Singapore

October 4, 2016
Sales and Marketing Sanofi, dengue, drug approval

Sanofi Pasteur, the vaccines unit of the wider French firm, has announced that its dengue vaccine Dengvaxia has secured market …

News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …

Feature
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016
Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …

News
merrimack-pharmaceuticals

Merrimack Pharmaceuticals’ CEO resigns and workforce cut by nearly a quarter

October 3, 2016
Sales and Marketing Gary Crocker, Merrimack Pharmaceuticals, Robert Mulroy

Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …

News
jj_2johnson_and_johnson

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

October 3, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …

News
eylea-product-box-md

Regeneron’s Eylea fails combination study endpoint

October 3, 2016
Research and Development, Sales and Marketing Eylea, Regeneron

Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …

News
novartis_window

Novartis reveals impressive four year data upon Cosentyx

October 3, 2016
Sales and Marketing Cosentyx, Novartis, psoriasis

Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …

News
shutterstock_168864905

GSK agrees to $20m settlement for Chinese bribery allegation

October 3, 2016
Business Services, Sales and Marketing China, GSK, GlaxoSmithKline

GlaxoSmithKline has agreed to settle a bribery allegation in China with a payment of $20 million to the US Securities …

News

Meet SHL at 2016 PDA Universe of Pre-filled Syringes & Injection Devices

October 3, 2016
Manufacturing and Production

At this year’s PDA Universe of Pre-filled Syringes & Injection Devices, SHL will be showcasing both new technologies and time-tested …

News
Press release
medimmune

AstraZeneca agrees $250 million licensing agreement with Allergan

October 3, 2016
Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease

Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026